ArticleCurrent microbiology2026
Sponge-Derived Streptomyces variabilis Extract Modulates Host Immune Gene Expression and Improves Survival in Caenorhabditis elegans During Vibrio parahaemolyticus Infection.
Article in Current microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vibrio parahaemolyticus is a major cause of seafood-borne gastroenteritis, and the emergence of antibiotic-resistant strains highlights the urgent need for alternative therapies. This study evaluated the antibacterial and immunomodulatory activity of mangrove sponge-associated actinomycetes (MSAS) using the Caenorhabditis elegans infection model. Eight actinomycete isolates were recovered from the sponge Haliclona sp., among which Streptomyces variabilis (MSAS7) emerged as the most promising candidate based on preliminary chemotaxis and toxicity screenings. The crude extract of S. variabilis (SVE) exhibited strong in vitro antibacterial activity, with inhibitory and bactericidal concentrations effective against V. parahaemolyticus. The in vivo assays demonstrated that SVE exhibited low toxicity in C. elegans and provided concentration-dependent protection, improving survival rates against V. parahaemolyticus infection to 80.89 ± 5.3%, while significantly reducing intestinal bacterial colonization without affecting feeding behavior. Targeted gene expression analysis revealed the upregulation of immunity-related genes (pmk-1, sek-1, lys-7, and snk-1), consistent with the activation of the p38 MAPK pathway. Chemical profiling putatively identified metabolites such as desferrioxamines E and D2, ikarugamycin epoxide, validamycin, albaflavenone, and saquayamycin B which have known antimicrobial and immunomodulatory functions. These results position mangrove sponge-derived S. variabilis as a compelling source of novel antimicrobial leads, offering a promising natural strategy to combat V. parahaemolyticus infections and mitigate the growing threat of antibiotic resistance.
Indexed as
Identifiers
41927987What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.